Clinical trials: Single Women
Healthy
Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers
The objective was to investigate the relative bioavailability of the fixed dose combination (FDC) tablet (80 mg telmisartan / 10 mg ramipril) after food intake in comparison to the bioavailability of the FDC tablet while fasting.
- Trial name
- NCT02214966
- Testing
- Telmisartan/Ramipril, fixed dose combination tablet, high fat, high caloric meal
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Healthy
CP-690,550 And Oral Contraception Drug-Drug Interaction Study
This study is designed to assess whether co-administration of CP-690,550 and oral contraceptives will effect the metabolism of the oral contraceptives in healthy volunteers.
- Trial name
- NCT01137708
- Testing
- ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Cancer Female
Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
Primary Objective: to assess the pathological Complete Response (pCR) rate in the breast of patients treated in following combinations: SAR240550 twice-weekly + weekly paclitaxel, SAR240550 weekly+ weekly paclitaxel, and weekly…
- Trial name
- SOLTI NEOPARP (NCT01204125)
- Testing
- paclitaxel, Iniparib (SAR2405550 -BSI-201)
- Where
- 25 sites in France, Germany and 1 more
- Volunteers
- 141 people
- Sponsor
- Sanofi
HPV-Related Cervical Carcinoma, HPV-Related Malignancy
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
This is a multi-center study in patients with recurrent or metastatic HPV16-positive, PD-L1 positive cervical cancer who has progressed during or after treatment with the first-line standard of care (pembrolizumab with…
- Conditions
- HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
- Trial name
- NCT06099418
- Testing
- VB10.16, Atezolizumab Injection [Tecentriq]
- Sponsor
- Nykode Therapeutics ASA
Platinum-resistant Ovarian Cancer
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.
- Trial name
- NCT04718376
- Testing
- Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
- Where
- 7 sites in China
- Volunteers
- 56 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Rheumatoid Arthritis, Renal Impairment
A Study of Fostamatinib in Subjects With Impaired Kidney Function
A 2 stage study to evaluate the amount of fostamatinib in the blood and urine in subjects with impaired kidney (renal) function compared with healthy volunteers with normal renal function.
- Trial name
- NCT01245790
- Testing
- fostamatinib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects
The objective of this study is to evaluate the relative bioavailability, and the rate and extent of absorption of bromocriptine in male and female children and adolescent Type 2 Diabetes Mellitus patients, aged 10 to less than…
- Trial name
- NCT02078440
- Testing
- Bromocriptine mesylate
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- VeroScience
Chronic Kidney Disease Stage 5
Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis
This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase administered to hemodialysis patients. A single dose of pegloticase will be administered intravenously to male or female hemodialysis patients…
- Trial name
- NCT01739660
- Testing
- Pegloticase
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Savient Pharmaceuticals
Healthy
A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865
The purpose of this study in healthy people is to evaluate safety, toleration and time course of plasma concentration of single oral doses of PF-06372865. The pharmacodynamic activity of PF-06372865 will also be assessed.
- Trial name
- NCT01951144
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hereditary Tyrosinemia, Type I
Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin
The purpose of this study is to determine whether Nitisinone 10 mg Tablets (Test Product 1 (TP1)) and Nitisinone 10 mg Tablets High Compritol (Test Product 2 (TP2)) are bioequivalent to the reference product Orfadin 10 mg…
- Trial name
- NCT02750709
- Testing
- Nitisinone, Nitisinone 10 mg Tablet High Compritol, Orfadin
- Where
- South Africa
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Schizophrenia, Psychiatric Disorders
Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
This trial is an open-label, multi-center, parallel-arm, single-dose trial in 2 groups: 1 group of subjects with normal renal function and 1 group of severely renally impaired subjects.
- Trial name
- NCT01289080
- Testing
- OPC-34712
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy Volunteers
A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477
The primary objective of the study is to assess the safety and tolerability of single ascending doses of REGN2477 in healthy women not of childbearing potential.
- Trial name
- NCT02870400
- Testing
- REGN2477
- Where
- Belgium
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Magnetic Resonance Imaging, Chronic Kidney Diseases
Study of Polyglycan Superparamagnetic Ferric Oxide Injection on Cardiovascular Magnetic Resonance Imaging
Polysaccharide super paramagnetic ferric oxide injection is an iron supplement developed for patients with iron deficiency anemia. Due to its characteristics, it has the potential to be a contrast agent.
- Trial name
- NCT05687864
- Testing
- Polysaccharide superparamagnetic ferric oxide injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Renal Impairment
Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment
The purpose of this study is to see how the body processes and gets rid of NVA237 in people who have impaired kidney function compared to people whose kidney function is normal.
- Trial name
- NCT01613690
- Testing
- NVA237
- Where
- Russia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Adult Male and Female Volunteers
A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:
The purpose of this study is to evaluate the bioavailability, safety and tolerability of Torasemide 10 mg tablets (Berlin-Chemie AG), compared to Unat® 10 tablets (Viatris Healthcare GmbH) in healthy adult participants under…
- Trial name
- NCT07201584
- Testing
- Torasemide tablet 10 mg, Unat® 10 tablets (Torasemide 10 mg)
- Where
- Kazakhstan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Berlin-Chemie AG Menarini Group
Migraine
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT04197349
- Testing
- ALD1910, Sumatriptan
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Renal Impairment
A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)
This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of a single dose of inclisiran subcutaneous (SC) injection in participants with mild…
- Trial name
- NCT03159416
- Testing
- Inclisiran
- Where
- 2 sites in New Zealand
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- The Medicines Company
Immunoglobulin A Nephropathy
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the…
- Trial name
- NCT07890909
- Testing
- Povetacicept, Sibeprenlimab
- Volunteers
- 40 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Phase 1, Healthy
EC905 Pharmacokinetic Profile Study
A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.
- Conditions
- Phase 1, Healthy, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
- Trial name
- NCT02634489
- Testing
- Tamsulosin HCl, Solifenacin Succinate, EC905
- Where
- Netherlands
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.